DYN Dyne Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development of product candidates for rare muscle diseases, leveraging manufacturing agreements with CMOs
• • New master manufacturing services agreements in 2025 securing $169.9M total fees committed through 2027 for product candidate components
• • Strategic emphasis on formalizing manufacturing capacity to support clinical and production scalability versus prior informal agreements
• • Notable R&D investment: $31.2M paid towards non-current assets under manufacturing agreement as of Dec 31, 2025, with additional $109.5M committed
• • Lease agreement for office and lab space with 8.5-year term started Sept 2021, with monthly rent increasing to $0.5M during term

Risk Factors

• • FDA clinical hold on z-rostudirsen IND in Jan 2022, delaying trial start until July 2022 clearance
• • Geopolitical and market risk from clinical and regulatory approval uncertainty in US and EU (FDA, EMA) regulatory agencies
• • Supply chain vulnerability in establishing manufacturing for Fab antibody, linker, therapeutic payload components for clinical and commercial supply
• • Competitive risk from delayed commercialization of product candidates until at least 2027, risking losing market share to established biotech peers
• • Financial risk from $1.4B accumulated deficit with net losses of $446.2M in 2025 and $317.4M in 2024, reliant on $1.1B cash runway to Q1 2028 and $275M Hercules loan facility with restrictive covenants

Management Discussion & Analysis

• • No revenue disclosed, focus on clinical development expenses for z-rostudirsen, z-basivarsen, FSHD and Pompe programs
• • No profitability or margin figures provided, expenses expected to increase with ongoing activities
• • No segment financial data; primary emphasis on research and development of multiple product candidates
• • Cash, cash equivalents, marketable securities sufficient to fund operations into Q1 2028
• • Capital needs to be met via equity, debt, collaborations, with risk of dilution and restrictive covenants; risk of delayed development if funding unmet

What are the latest DYN SEC filings in 2026?

Dyne Therapeutics, Inc. (DYN) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on July 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DYN file its most recent 10-K annual report?

Dyne Therapeutics, Inc. (DYN) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DYN 10-Q quarterly reports?

Dyne Therapeutics, Inc. (DYN)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every DYN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DYN filed recently?

Dyne Therapeutics, Inc. (DYN)'s most recent 8-K was filed on July 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DYN insider trading activity (Form 4)?

SignalX aggregates every DYN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DYN file with the SEC?

Dyne Therapeutics, Inc. (DYN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DYN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Dyne Therapeutics, Inc. (DYN).

What is DYN's SEC CIK number?

Dyne Therapeutics, Inc. (DYN)'s SEC CIK (Central Index Key) number is 1818794. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1818794 to look up all DYN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DYN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Dyne Therapeutics, Inc. (DYN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.